Annexon (NASDAQ:ANNX) Releases Earnings Results, Misses Expectations By $0.07 EPS

Annexon (NASDAQ:ANNX) issued its quarterly earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07), Zacks reports.

Annexon Stock Up 9.7%

Shares of ANNX stock traded up $0.16 during trading hours on Monday, hitting $1.76. 444,347 shares of the company’s stock were exchanged, compared to its average volume of 1,588,742. The firm has a 50 day moving average of $2.00 and a two-hundred day moving average of $3.82. Annexon has a fifty-two week low of $1.28 and a fifty-two week high of $7.85. The firm has a market cap of $192.55 million, a P/E ratio of -1.68 and a beta of 1.24.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.